AbbVie Subsidiary Moves to Acquire Soliton, RAP Device for $550 Million

AbbVie’s Allergan Aesthetics will purchase rapid acoustic pulse devicemaker Soliton for $550 million in a move to expand its body contouring treatment product range.

Through the agreement, Allergan Aesthetics will acquire Soliton’s Resonic device, a non-invasive rapid acoustic pulse system cleared by the FDA for the short-term improvement of cellulite appearance and for tattoo removal when used with a laser.

The device uses rapid, high-frequency sound waves to disrupt cellular structures and connective tissue and reduce the dimpled appearance of cellulite.